Masuishi T, Tsuji A, Kotaka M, Nakamura M, et al. Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. Br J Cancer 2020 Aug 31. pii: 10.1038/s41416-020-01042.
PMID: 32863385